

mariposa HEALTH

Shareholder Newsletter March 2013

Dear Shareholder,

I am pleased to advise that Mariposa Health has now completed the acquisition of Hunter Immunology. With this acquisition our respiratory drug development program, and our risk:benefit profiles have been strengthened (see attached announcement by Bioxyne; ASX Code BXN).

In third quarter of last year, we had indicated that we were seeking business development opportunities in China. With completion of the acquisition of Hunter Immunology, this now allows us to proceed at full speed in this direction. We have signed a non-binding agreement with a significant Chinese Pharma for the commercial development of COPD projects in the PR China, Taiwan, Hong Kong and Macau.

The Company is also in discussion with advisors to assist us with a similar transaction path for the EU, US and the rest of Asia. On a cautious note, at this time, we can provide no certainty as to the timing of completing a transaction or whether one will be completed.

Our challenge is to continue to add value to the program while being active in positioning ourselves for out-licensing opportunities.

Funding for the acquisition of Hunter Immunology was provided by clients of Novus Capital. The Company will offer you the opportunity to invest at the same price offered Novus clients with will allow you to maintain or increase your shareholding as a percent of the total number of shares on issue.

The last few months have seen significant changes in our profile and for that we are thankful for your support. The next few months will see us endeavouring to complete the out-licensing for PR China and, depending on financial markets, provide clarity on the timetable to listing on the ASX. Please feel welcome to call me to discuss any of the above matters.

Yours faithfully,

Phillip Comans
Executive Chairman